1
/
of
1
Afatek (Afatinib)
Afatek (Afatinib)
Regular price
₱64,000.00 PHP
Regular price
Sale price
₱64,000.00 PHP
Unit price
₱2,133.33 each
Taxes included.
Quantity
Couldn't load pickup availability
Afatek (Afatinib) is an advanced antineoplastic agent designed for targeted cancer therapy, specifically indicated for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) in patients with EGFR mutations or those showing resistance to platinum-based chemotherapy regimens.
As a selective inhibitor of epidermal growth factor receptor (EGFR), Afatinib works by blocking the activity of mutated EGFR proteins that drive cancer cell growth and proliferation. This targeted mechanism makes it particularly effective for NSCLC patients harboring specific EGFR mutations, including exon 19 deletions and exon 21 (L858R) substitution mutations, which are common in Asian populations and associated with improved treatment response.
Afatinib is primarily prescribed for first-line and subsequent-line treatment of metastatic NSCLC with activating EGFR mutations, offering patients an oral medication option that can be integrated into a comprehensive cancer care plan. The medication is typically administered as directed by an oncologist, with dosing individualized based on patient tolerability and clinical response.
Important considerations include hypersensitivity precautions for patients with documented allergies to Afatinib or its formulation components. Caution is advised in patients with hepatic or renal impairment, as dose adjustments may be necessary. Afatinib is contraindicated during pregnancy and breastfeeding due to the risk of fetal harm and potential transfer into breast milk.
Patients taking Afatinib require ongoing medical supervision and should not initiate, continue, or modify treatment without explicit guidance from their oncologist. Regular monitoring for efficacy and adverse effects is essential for optimal therapeutic outcomes.
As a selective inhibitor of epidermal growth factor receptor (EGFR), Afatinib works by blocking the activity of mutated EGFR proteins that drive cancer cell growth and proliferation. This targeted mechanism makes it particularly effective for NSCLC patients harboring specific EGFR mutations, including exon 19 deletions and exon 21 (L858R) substitution mutations, which are common in Asian populations and associated with improved treatment response.
Afatinib is primarily prescribed for first-line and subsequent-line treatment of metastatic NSCLC with activating EGFR mutations, offering patients an oral medication option that can be integrated into a comprehensive cancer care plan. The medication is typically administered as directed by an oncologist, with dosing individualized based on patient tolerability and clinical response.
Important considerations include hypersensitivity precautions for patients with documented allergies to Afatinib or its formulation components. Caution is advised in patients with hepatic or renal impairment, as dose adjustments may be necessary. Afatinib is contraindicated during pregnancy and breastfeeding due to the risk of fetal harm and potential transfer into breast milk.
Patients taking Afatinib require ongoing medical supervision and should not initiate, continue, or modify treatment without explicit guidance from their oncologist. Regular monitoring for efficacy and adverse effects is essential for optimal therapeutic outcomes.
Share
